Biography

Consultancy In Topical And Transdermal Drug Delivery

Adam has a wealth of experience in the area of pharmaceutical development in general, and transdermal and topical drug delivery in particular. Until May 2011 he was Chief Scientific Officer at Acrux in Melbourne, Australia, where his responsibilities included the strategic leadership of product development and provision of technical support to commercial partnering activities. He was also heavily involved in regulatory affairs and has significant experience of the approval process in the US and Europe. During his six years with Acrux he was a key member of the senior management team and played a pivotal role in the development and approval of Axiron®, a novel transdermal testosterone product that was subsequently licensed to and launched (March 2011) by Eli Lilly in the US (www.axiron.com).

Prior to Acrux, Adam worked at ProStrakan in Scotland as a Project Manager and Drug Delivery Research Manager. Whilst at ProStrakan he initiated and managed the early development of Sancuso®, the first transdermal granisetron patch that was launched by ProStrakan in the US in 2008 (www.sancuso.com) and approved in the EU in 2012. Before his five year stint at ProStrakan, Adam played key roles at An-eX in Wales, a company that provides R&D development services in the area of percutaneous absorption to the pharmaceutical, cosmetic and agrochemical industries.

Adam has an MBA from Cardiff University, a PhD from the Welsh School of Pharmacy in the area of transdermal delivery and a BSc in Chemistry from the University of Bath. He has published extensively on his research and over the years has held honorary positions at The University of Cardiff, The University of London and Monash University in Melbourne (Australia). He is currently a Visiting Research Professor at the School of Pharmacy at Queens University in Belfast. Despite his allegiance to industry he has co-supervised several PhD students and is an advocate of encouraging students to interact with industry as early and as much as possible. The Royal Society of Chemistry (RSC) awarded Adam Fellow membership (FRSC) in 2018.

Adam is co-editor of the book "Transdermal and Topical Drug Delivery - Principles and Practice" published by John Wiley & Sons in January 2012.